Literature DB >> 17852114

Fractionated (split dose) radiosurgery in patients with recurrent brain metastases: implications for survival.

P Davey1, M L Schwartz, D Scora, S Gardner, P F O'Brien.   

Abstract

Radiosurgery is conventionally prescribed for brain metastases with a single dose of radiation. Fractionation has been advocated to improve tumour control. A multivariate analysis of prognostic factors including fractionation has been performed in two consecutive prospective radiosurgery protocols with and without fractionation in order to identify an association, if any, between fractionation and survival. A surgically applied stereotactic head frame was used. Radiosurgery planning was based on a contrast-enhanced CT. Sixty-nine patients underwent the two-fraction regimen and 35 patients had a single treatment. Multivariate analysis showed that the presence of extracranial malignancy, performance status, multiple brain metastases, patient gender and the time from the initial treatment to radiosurgery were independent determinants for survival. Fractionation was also an independent determinant with two-fraction patients surviving a median of 30 weeks versus single fraction patients who survived a median of 16 weeks. Fractionated radiosurgery was associated with improved survival and deserves further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17852114     DOI: 10.1080/02688690701534722

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  6 in total

1.  American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS).

Authors:  Steven K Seung; David A Larson; James M Galvin; Minesh P Mehta; Louis Potters; Christopher J Schultz; Santosh V Yajnik; Alan C Hartford; Seth A Rosenthal
Journal:  Am J Clin Oncol       Date:  2013-06       Impact factor: 2.339

2.  CyberKnife Radiosurgery in Recurrent Brain Metastases: Do the Benefits Outweigh the Risks?

Authors:  Romagna Alexander; Christoph Schwartz; Barbara Ladisich; Wolfgang Hitzl; Sarah-Charlotta Heidorn; Peter A Winkler; Alexander Muacevic
Journal:  Cureus       Date:  2018-12-17

Review 3.  Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review.

Authors:  Maxime Loo; Jean-Baptiste Clavier; Justine Attal Khalifa; Elisabeth Moyal; Jonathan Khalifa
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

Review 4.  The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mario Ammirati; Charles S Cobbs; Mark E Linskey; Nina A Paleologos; Timothy C Ryken; Stuart H Burri; Anthony L Asher; Jay S Loeffler; Paula D Robinson; David W Andrews; Laurie E Gaspar; Douglas Kondziolka; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

5.  Optically-guided frameless linac-based radiosurgery for brain metastases: clinical experience.

Authors:  Sameer K Nath; Joshua D Lawson; Jia-Zhu Wang; Daniel R Simpson; C Benjamin Newman; John F Alksne; Arno J Mundt; Kevin T Murphy
Journal:  J Neurooncol       Date:  2009-08-23       Impact factor: 4.130

6.  Treatment of malignant tumors of the skull base with multi-session radiosurgery.

Authors:  Nicholas D Coppa; Daniel M S Raper; Ying Zhang; Brian T Collins; K William Harter; Gregory J Gagnon; Sean P Collins; Walter C Jean
Journal:  J Hematol Oncol       Date:  2009-04-02       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.